Market Signal Briefing

Bitcoin's price movement diverged from the Nasdaq futures, which fell nearly 0.8%.

Privacy tokens are back in focus, and Monero is leading the charge. The XMR price decisively broke above a crucial resistance zone to reach fresh all-time highs near $596.87. The move was backed by a sharp expansion in trading volume, highlighting strong buyer conviction. As market sentiment turns risk-on within the privacy coin segment, Monero’s breakout signals a shift into a stronger bullish phase.

Monero is rising today as privacy coins regain market attention and capital rotates into anonymity-focused assets. The move into new all-time high territory has attracted momentum traders, pushing prices closer to the key $600 psychological level. At the same time, uncertainty surrounding rival privacy projects, like Zcash, has strengthened demand for XMR. With bullish technical structure and sustained volume inflows, Monero’s rally appears primed to maintain an upside trajectory.

What’s Next for the XMR Price Rally? The XMR price has decisively broken out of a multi-year structure that had remained intact since the 2021 market top. Monero surged above the neckline of a large cup-and-handle pattern, a classic bullish formation that typically signals trend continuation. Based on this setup, the projected breakout target is measured by the depth of the cup, pointing to levels well above $1,000. With the broader structure suggesting a long-term objective near $1,600. 

After posting a strong and consistent advance throughout 2024 and 2025, Monero now enters 2026 at a critical juncture. This raises the key question of whether bullish momentum can be sustained at higher price zones.

The liquidity flow indicator, CMF, displays a consistent inflow of capital since the 2021 bull run, as the levels have never dropped below 0 in the weekly chart. Besides, the MACD is replicating a similar move observed during the bull run period, where it soared high after a prolonged consolidation. This suggests buying pressure has been mounted to a large extent, which could help the bulls to maintain a strong upswing.  

When a positive CMF aligns with expanding MACD momentum, it usually hints at a healthy bull trend with follow-through potential. For Monero, this suggests buyers remain in control and that pullbacks, if any, are more likely to be consolidations than trend reversals. This setup could weaken only if CMF drops back to 0 and MACD flattens and rolls over while price stalls near resistance. Until then, indicators favor a continued upside trajectory, but not a cycle top. 

Will Monero (XMR) Price Reach $1000?With Monero breaking into price discovery and holding above its former multi-year resistance, the broader structure remains decisively bullish. In the near term, the next logical upside zone lies between $650 and $720, where minor historical extensions and psychological resistance may trigger consolidation. A sustained move above this range would strengthen the case for a medium-term advance toward $850–$1,000. 

While a direct rally to $1,000 may not be immediate, current momentum, strong volume inflows, and bullish indicators suggest the level is realistic in the coming months. Provided broader market conditions remain supportive and Monero (XMR) price maintains its breakout structure.

Trust with CoinPedia:CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.

Sponsored and Advertisements:Sponsored content and affiliate links may appear on our site. Advertisements are marked clearly, and our editorial content remains entirely independent from our ad partners.

Bitcoin and major cryptocurrencies rose late Sunday, as traders weighed macroeconomic tailwinds following a warning from Federal Reserve Chair Jerome Powell about political pressure on the central bank.

Bitcoin rose 1.5% to $92,047 as of 11:30 p.m. ET Sunday, while Ethereum gained 1.99% to $3,157, according to The Block's price page. Solana led among major altcoins with a 4.81% jump to $142.53. 

The rally was spotted across the broader crypto market, where privacy-focused tokens stood out as the biggest winners. Monero surged 17.9% to $574.09, and Zcash climbed 9.76% to $410.92.

The price action came shortly after Powell disclosed in a video message that the U.S. Department of Justice had threatened criminal indictment related to his testimony at Congress in June 2025. 

"The threat of criminal charges is a consequence of the Federal Reserve setting interest rates based on our best assessment of what will serve the public, rather than following the preferences of the President," said Powell, whose term as Fed chair is scheduled to end in May 2026.

U.S. President Donald Trump has been a vocal critic of Powell over disagreements on the pace and depth of interest rate cuts. Trump has repeatedly pressed the Fed for deeper and faster cuts, calling for a benchmark of 1% or lower.

Safe-haven rotation Peter Chung, head of research at Presto Research, said bitcoin's rally "started right around the time Jerome Powell's video was released," noting that gold rose sharply at the same moment. Spot gold price rose 1.3% to $4,569 at the time of writing.

"These price actions strongly suggest that Powell's remark that the Fed's independence is under threat have triggered investor concerns over the USD-led legacy financial system," Chung said, adding that confidence in the dollar's neutrality is central to its reserve-currency status. "Once the public sufficiently believes this is no longer the case, investors will start to look for hedges against the legacy system, and gold and BTC are those hedges."

Vincent Liu, CIO of Kronos Research, told The Block that technical levels and strategic buying added momentum.

"BTC and ETH climbed on technical support and strategic buying at key levels," Liu said. "Traders are eyeing these moves amid updates on the  broader regulatory chatter, including news on the potential digital-asset market-structure bill to boost transparency and liquidity."

Liu added that traders are closely watching three catalysts this week: Powell's clash with the DOJ, updates around tax-cut plans, and Tuesday's upcoming U.S. Consumer Price Index reading. 

Macro resilience Jeff Mei, COO at BTSE, cautioned that sharp moves could emerge during the U.S. market open, given heightened political tensions. "Because of the Trump-Fed spat, it’s possible that the market may dip upon its open U.S. time," he said. 

However, Jeff Ko, chief analyst at CoinEx Research, downplayed the direct impact of the DOJ-Fed dispute, describing it instead as part of a broader narrative around policy uncertainty. Ko said the macro backdrop remains constructive for crypto, citing softer-than-expected non-farm payrolls, rising gold prices, and a recent deleveraging reset. 

Ko noted that geopolitical flare-ups remain a key risk. "Any escalation could significantly amplify market volatility and safe-haven flows," he added.

Andri Fauzan Adziima, research lead at Bitrue, said strong U.S. fundamentals are driving sustained momentum, noting that robust GDP growth, rising real wages, and moderating inflation naturally favor risk-on assets.

His views came as Goldman Sachs revised its interest-rate outlook, postponing its forecast for Fed rate cuts to June and September 2026 from its previous projection of March and June, Reuters reported on Sunday.

"Anticipated Federal Reserve rate reductions, most likely in June and September, will further ease financial conditions, injecting liquidity that cryptocurrencies historically absorb with vigor and signaling the early stages of a sustained bullish phase," Adziima added.

Disclaimer: The Block is an independent media outlet that delivers news, research, and data. As of November 2023, Foresight Ventures is a majority investor of The Block. Foresight Ventures invests in other companies in the crypto space. Crypto exchange Bitget is an anchor LP for Foresight Ventures. The Block continues to operate independently to deliver objective, impactful, and timely information about the crypto industry. Here are our current financial disclosures.

© 2026 The Block. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Token unlocks totaling over $1.69 billion are scheduled for the week of January 12-19, 2026, according to data from Tokenomist.

ONDO leads cliff unlocks with 1.94 billion tokens worth $772.42 million, representing 57.23% of adjusted released supply. TRUMP follows with 55.10 million tokens valued at $299.17 million.

ONDO dominates cliff token unlocks with $772.42M ONDO leads all token unlocks for the January 12-19 week with 1.94 billion tokens worth $772.42 million. The unlock represents 57.23% of adjusted released supply. It is also the largest single token unlock event.

TRUMP posts the second-largest cliff unlock with 55.10 million tokens valued at $299.17 million. The unlock accounts for 13.30% of adjusted released supply. TRUMP also appears in linear unlocks with the same 55.10 million tokens representing 27.55% of circulating supply.

CONX unlocks 1.32 million tokens worth $20.59 million, representing 1.59% of adjusted released supply. Arbitrum (ARB) releases 96.00 million tokens valued at $19.56 million, accounting for 1.68% of supply. DBR unlocks 618.33 million tokens worth $11.52 million, a substantial 14.81% of adjusted released supply.

Token unlock data: Tokenomist CHEEL releases 20.81 million tokens valued at $11.50 million, representing 2.78% of supply. Starknet (STRK) unlocks 127.00 million tokens worth $10.33 million, accounting for 4.83% of adjusted released supply. SEI releases 75.80 million tokens valued at $9.15 million, representing 1.44% of supply.

ZK completes the major cliff unlocks with 173.08 million tokens worth $5.89 million, representing 3.16% of adjusted released supply. The nine cliff unlocks total approximately $1.16 billion in value. The concentration in ONDO and TRUMP means these two projects account for 92.4% of cliff unlock value.

Linear token unlocks add $537M in weekly releases RAIN leads linear token unlocks with 9.41 billion tokens worth $84.13 million scheduled for the week. The unlock represents 2.77% of circulating supply.

Solana unlocks 482,400 tokens worth $67.14 million, or just 0.09% of circulating supply. TRUMP makes its second appearance with 55.10 million tokens in linear releases worth $299.17 million, or 27.55% of circulating supply.

Worldcoin releases 37.23 million tokens worth $21.13 million, 1.37% of circulating supply; RIVER unlocks 1.25 million tokens worth $21.02 million, or a quite reasonable 6.38% of the circulating supply. DOGE has unlocked 97.56 million tokens worth $13.42 million, which is just 0.06% of the huge circulating supply.

Avalanche finally unlocks 700,000 tokens worth $9.57 million, about 0.16% of the circulating supply. ASTER releases 10.28 million tokens worth $7.34 million, 0.43% of supply. Bittensor finally unlocks 25,200 tokens worth $7.22 million, representing 0.26% of the circulating supply.

Smaller projects face unlock schedules Masters of Trivia (MOT) shows 4.83% unlock progress with the next release of 5.5 million MOT tokens worth $17.92 million. The unlock represents 1.10% of total locked supply. The trivia gaming project maintains relatively low unlock progression.

HyperGPT (HGPT) shows 86.04% unlock progress with the next release of 13.92 million HGPT tokens worth $71,884.74. Checkmate (CHECK) shows 18.18% unlock progress with the next release of 16.77 million CHECK tokens worth $1.32 million. The unlock represents 1.68% of total locked supply.

BounceBit (BB) shows 44.53% unlock progress with the next release of 32.78 million BB tokens worth $2.08 million. The unlock represents 1.56% of total locked supply. DappRadar (RADAR) shows 79.12% unlock progress with the next release of 107.89 million RADAR tokens worth $50,961.16.

Sharpen your strategy with mentorship + daily ideas - 30 days free access to our trading program

Binance Coin climbed again over the weekend, pushing past the $900 mark and touching about $907 on Sunday after a sharp 24-hour uptick. Markets were calmer overall, with the broader crypto complex up 0.55% for the day while Bitcoin hovered above $92,000 and Ethereum traded beyond $3,100.

Market Reaction To Regulatory Shift According to social posts from Changpeng Zhao, founder and former CEO of Binance who is also known as ‘CZ’, optimism around a possible new crypto cycle helped fuel demand. CZ linked the mood to a regulatory change, saying the Securities and Exchange Commission had removed crypto from its list of priority risks for 2026.

Based on reports, that move is being read by some investors as a sign of easing scrutiny, and it appears to have lifted sentiment across tokens.

I could be wrong, but Super Cycle incoming. https://t.co/6TLldEMmGA

— CZ 🔶 BNB (@cz_binance) January 10, 2026

Institutional Buying Adds Fuel Reports note sizable institutional flows into Bitcoin products. According to a filing, Wells Fargo bought 383 million of Bitcoin ETF shares, a figure that market watchers flagged as a large institutional stake.

Morgan Stanley also filed for its own spot Bitcoin ETF last week, which many see as more proof that big financial players are stepping in. Those actions are being cited by traders as one reason risk assets like Binance Coin could see more interest.

BNBUSD now trading at $909. Chart: TradingView Macroeconomic Calendar Could Swing Prices A packed US data week is ahead and traders say it could affect crypto angles. On Monday, the market will watch a speech by the FOMC president. On Tuesday and Wednesday, the US Consumer Price Index and the Producer Price Index are due.

Jobless claims come on Thursday, and a Fed balance sheet update lands on Friday. Any big surprise in those numbers can push liquidity flows and quickly change appetite for tokens.

Binance Coin: Technical Levels To Watch BNB briefly reclaimed the $900 zone and was reported at $909 in some feeds as the four-hour chart showed a steady climb. Short-term resistance sits near $950, with a psychological barrier at $1,000.

Technical indicators offered cautious support for bulls: the MACD showed a bullish crossover with the blue line above the signal line, and the histogram printed positive bars, which suggests buying pressure building. The RSI sat around 56.10, under overbought levels, implying room for more gains.

Traders still point to a key support range near $850. A break below that could invite heavier selling and take prices down toward $820. The scenario of a quick pullback is real; prices that move fast up can move fast down. Market participants will be watching both the macro calendar and any fresh regulatory updates for clues.

Featured image from Unsplash, chart from TradingView

Tony Kim Jan 12, 2026 07:06

Binance Coin shows bullish momentum with MACD confirmation at $907. Technical analysis suggests BNB could target $950-$1,100 in coming weeks if it breaks key resistance.

BNB Price Prediction Summary • Short-term target (1 week): $950 • Medium-term forecast (1 month): $950-$1,100 range
• Bullish breakout level: $927.71 • Critical support: $877.53

What Crypto Analysts Are Saying About Binance Coin While specific analyst predictions are limited in the past 24 hours, recent forecasts from major platforms paint an optimistic picture for Binance Coin. CoinCodex projects BNB trading between $837.42 and $1,386.60 throughout 2026, with an average annualized price of $1,096.69. This Binance Coin forecast aligns with bullish momentum indicators currently visible on-chain.

Coinbase's analysis suggests a more conservative but still positive outlook, targeting $1,143.44 over the next five years, representing a 27.6% increase from current levels. According to technical data from major exchanges, BNB's current positioning above key moving averages supports these bullish projections.

BNB Technical Analysis Breakdown The technical landscape for BNB presents a compelling bullish setup. At $907.51, Binance Coin trades well above its 20-day SMA of $877.53 and 50-day SMA of $876.04, indicating strong upward momentum.

The RSI reading of 58.82 places BNB in neutral territory, providing room for further upside without entering overbought conditions. The MACD histogram at 0.0000 with bullish momentum confirmation suggests buyers are gaining control after recent consolidation.

Binance Coin's position within the Bollinger Bands is particularly noteworthy. With a %B position of 0.78, BNB trades closer to the upper band ($931.13) than the lower band ($823.92), indicating sustained buying pressure. The middle band at $877.53 now serves as dynamic support.

Key resistance levels stand at $917.61 (immediate) and $927.71 (strong), while support rests at $897.13 and $886.75. The daily ATR of $22.00 suggests moderate volatility, typical for BNB's current price range.

Binance Coin Price Targets: Bull vs Bear Case Bullish Scenario A break above the strong resistance at $927.71 could trigger the next leg higher toward $950-$980. This BNB price prediction hinges on maintaining volume above the current 24-hour average of $102.8 million and RSI staying below 70.

Further upside targets include the psychological $1,000 level, followed by CoinCodex's projected range ceiling around $1,100. The bullish case strengthens if BNB can establish $927 as new support, creating a foundation for testing higher resistance zones.

Bearish Scenario Failure to hold the pivot point at $907.23 could see BNB retesting the 20-day SMA support at $877.53. A break below this crucial level would target the strong support zone around $886.75, with further downside toward $850 if selling pressure intensifies.

The bearish scenario activates if RSI drops below 50 and the MACD turns negative, suggesting momentum has shifted in favor of sellers. Volume expansion on any decline would confirm the bearish thesis.

Should You Buy BNB? Entry Strategy Current technical conditions suggest strategic entry points for BNB positions. Conservative buyers should consider accumulating on any pullback toward the $897-$900 support zone, using the 20-day SMA at $877.53 as a stop-loss level.

More aggressive traders might enter above $917.61 breakout confirmation, targeting the $950-$980 range with stops below $900. This Binance Coin forecast supports a risk-managed approach given the neutral RSI reading and bullish MACD configuration.

Position sizing should account for BNB's $22 daily ATR, allowing for normal volatility while protecting capital. The current setup favors buyers, but prudent risk management remains essential.

Conclusion The BNB price prediction for the coming month appears constructive, with technical indicators supporting a move toward $950-$1,100. The combination of bullish momentum indicators, favorable positioning within Bollinger Bands, and analyst forecasts from major platforms suggests Binance Coin could outperform in February 2026.

However, crypto markets remain highly volatile and unpredictable. This analysis should not constitute financial advice, and investors should conduct their own research and consider their risk tolerance before making investment decisions. Price predictions are inherently speculative and subject to rapid change based on market conditions.

Image source: Shutterstock

bnb price analysis bnb price prediction

Recent turmoil in Venezuela and Iran has again put the spotlight on the duality of stablecoins, with the US dollar-backed assets such as Tether acting as both a savior for embattled citizens and a tool for blacklisted entities to evade sanctions. 

Both Venezuela and Iran have been catching headlines at the beginning of 2026 amid political uncertainty and civil unrest. With both facing a host of sanctions, inflation, political instability, and a cost-of-living crisis, crypto and stablecoins have become an important part of the ecosystem. 

Iran’s stablecoin entanglementIran has seen protests erupt across the country over the past two weeks in response to worsening economic conditions and the Iranian rial tanking to record lows against the US dollar.  

The situation has escalated from local demonstrations to widespread protests across Iran, with thousands arrested and hundreds reportedly killed. Amid this backdrop, the Iranian government also moved to cut off domestic internet access on Thursday. 

Crypto and stablecoins have become an important tool for citizens in Iran, given that the Iranian rial has been plummeting in value against the US dollar for decades.

Tron-based Tether (USDT) is reportedly the most utilized asset in the country, with citizens using the asset to hedge inflation and systemic risk.  

Broader adoption took a hit in 2025, however, with a hack on the country’s biggest exchange and a significant number of Tether blacklistings. Meanwhile, the government also set an annual limit on stablecoins in late September, allowing citizens max holdings of $10,000 and max purchases of per person $5,000. 

But stablecoins have also been used by sanctioned entities. A report from blockchain analytics firm TRM Labs on Friday indicates that since 2023, Iran’s Islamic Revolutionary Guard Corps (IRGC) has moved over a $1 billion worth of stablecoins via two “UK-based front companies” called Zedcex and Zedxion. 

The report claimed that despite the two firms publicly presenting themselves as individual firms, they have been quietly functioning together “as financial infrastructure for the IRGC.”  

“In practice, they operate as a single enterprise embedded within a broader Iranian sanctions evasion ecosystem, moving value across borders, currencies, and jurisdictions on behalf of one of the world’s most heavily sanctioned military organizations,” TRM Labs said. 

“A key figure in this network is Babak Zanjani, a longtime Iranian sanctions-evasion financier previously sanctioned for laundering billions in oil revenue on behalf of regime entities, including the IRGC,” TRM Labs added.  

Venezuela is closely entwined with USDT Similar to Iranians, Venezuelans have also adopted USDT to protect themselves against economic uncertainty, as the Venezuelan bolivar has plummeted over the past decade. 

A severe lack of trust in banks has reportedly seen USDT so widely adopted that everyday people use the asset to pay for all kinds of everyday services, opting to set up crypto wallets instead of using bank accounts. 

“It’s how you pay your landscaper and how you pay for your haircut. You can use tether basically for anything,” 71-year-old Venezuelan crypto entrepreneur Mauricio Di Bartolomeo told the Wall Street Journal on Saturday, adding: 

“Stablecoin adoption has gone so far into Venezuela that even without having regulated venues where you can buy and sell them, people still choose to go for stablecoins as opposed to using the local banks.”The WSJ also highlighted that USDT is highly utilized by Venezuela’s state-run oil company, Petroleos de Venezuela. The firm reportedly started demanding payments directly in the stablecoin to avoid sanctions that were first imposed back in 2020. 

The company is estimated to accept 80% of all its oil revenue via Tether and frequently uses the asset to settle incoming and outgoing payments.

Tether uses blacklists to fight sanction evadersThe WSJ report adds that Tether has been fighting this by cooperating with the US government to blacklist “dozens of wallets” tied to the domestic oil trade. 

According to data compiled in a Dec. 5 report from AMLBot, Tether blacklisted around $3.3 billion worth of funds between 2023 and late 2025, with $1.75 billion of that sum being frozen Tron-based USDT. 

Over the weekend, the firm reportedly added to the figure by freezing $182 million worth of Tron-based USDT across five wallets; however, this has not been confirmed to be related to Venezuela or Iran. 

Cointelegraph has reached out to Tether for comment.

Source: @0xG00gly Magazine: How crypto laws changed in 2025 — and how they’ll change in 2026

Cointelegraph is committed to independent, transparent journalism. This news article is produced in accordance with Cointelegraph’s Editorial Policy and aims to provide accurate and timely information. Readers are encouraged to verify information independently. Read our Editorial Policy https://cointelegraph.com/editorial-policy

Bitcoin price traded in a tight range over the weekend, absorbing selling pressure while defending the critical $90,000 support zone. The rebound from this level was backed by strong buying volume, allowing BTC to open the week on a firmer note and push back toward its immediate resistance area.

Strategy Inc. (NASDAQ:MSTR) Executive Chair Michael Saylor highlighted on Sunday that the company has surpassed Wall Street giants since adopting the Bitcoin (CRYPTO: BTC)-focused approach, trailing only Nvidia Corp. (NASDAQ:NVDA).

Saylor posted a chart on X comparing annualized returns for various assets during the “Bitcoin Standard Era,” referring to the period since Aug. 10, 2020, when the company adopted Bitcoin as its primary treasury reserve asset. 

During this period, Nvidia surged by 1,557%, with a compound annual growth rate of 68%. Strategy stood second in the list, gaining 1,173% with annualized returns of 60%.

Bitcoin, the asset around which Strategy has built its operations, has risen 674% since Aug. 10, 2020, equating to an annualized gain of 45%.

Saylor named Nvidia “Digital Intelligence,” MSTR stock “Digital Credit,” and Bitcoin “Digital Capital” as the decade’s “best-performing assets.”

Strategy’s Decline In 2025While Strategy has indeed outperformed the “Mag 7” giants over a broader timeframe, its performance lately has lagged significantly.

Over the last year, it has lost 52% of its value, while Nvidia, Tesla Inc. (NASDAQ:TSLA), Microsoft Corp. (NASDAQ:MSFT) and Alphabet Inc. (NASDAQ:GOOG) have all generated returns for their shareholders.

Gains Since Aug. 10, 2020 +/-Gains StrategyNvidia               TeslaAlphabetMicrosoftAssets1-Year +/-10-Year Gains +/-+1,173%-52.09%+923.08%+1,557%+38.73%+24,376.66%+371%+10.34%+3.054.61%+342%+71.17%+818.60%+137%+14.88%+808.42%Will MSTR Bounce Back Strongly?The MSTR stock is often seen as a leveraged Bitcoin proxy due to its recursive strategy of issuing equity and debt to acquire more BTC as its price rises. However, this connection also causes it to suffer when the price of BTC drops, which is what happened last year.

The company announced a $1.44 billion reserve last year, aimed at funding dividends and interest without relying on Bitcoin sales during downturns.

Strategy's market valuation stands at $49.21 billion, while its Bitcoin holdings are valued at a little over $62 billion. This means that the stock is trading at a discount to its net asset value, or NAV.

Price Action: At the time of writing, BTC was exchanging hands at $92,034.52, up 1.56% in the last 24 hours, according to data from Benzinga Pro.

Strategy shares closed 5.77% lower at $157.33 during Friday’s regular trading session.

The stock maintains a weaker price trend over the short, medium and long terms. How does it compare with Nvidia? Visit Benzinga Edge Stock Rankings to find out.

Photo Courtesy: yanadhorn on Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Tether has frozen approximately $182 million worth of USDT on the Tron network. The action, executed on January 12, seems to be in cooperation with law enforcement agencies. This enforcement step is one of Tether’s largest on a single day and is reportedly in connection with potential illicit activities.

The move by Tether, a major player in the stablecoin market, underscores its ongoing efforts to comply with regulatory and legal requirements. The company’s decision comes amid heightened scrutiny of the crypto sector, where regulatory bodies frequently focus on compliance measures to prevent money laundering and other illegal activities.

The Tether stablecoin, USDT, is widely used for transactions across various blockchain networks, including Tron. Such actions to freeze assets are typically aimed at curbing illegal financial activities by halting the movement of suspect funds. Tether’s ability to freeze assets is a part of its centralized control over the issuance and redemption of USDT, allowing the company to act swiftly in response to regulatory or law enforcement requests.

Market participants and observers have taken note of Tether’s action, which highlights the increasing role of stablecoins in the financial ecosystem and their susceptibility to regulatory oversight. The crypto market often faces challenges related to compliance and the prevention of illicit transactions, which are key concerns for regulators worldwide.

The move by Tether also reflects the broader context of regulatory engagement with the cryptocurrency industry. Regulatory bodies are focused on ensuring market integrity, investor protection, and transparency in crypto transactions. This includes oversight on custodial practices, market surveillance, and sharing of information with law enforcement when necessary.

Stablecoin issuers like Tether are under continuous pressure to maintain compliance with these regulatory standards while providing a reliable and stable digital currency option for users. The enforcement actions undertaken by Tether demonstrate its commitment to adhere to these standards and cooperate with authorities to maintain the integrity of the financial system.

As the largest cryptocurrency by market capitalization, Bitcoin often sets the context for discussions on digital assets. However, stablecoins like USDT play a critical role in bridging traditional finance and the crypto world, providing a stable store of value and unit of exchange.

The incident also brings attention to the operational capabilities of stablecoins, including their ability to respond to legal and compliance challenges. Regulators and market participants alike are closely monitoring how stablecoin issuers navigate these complex legal frameworks and their impact on the broader financial markets.

Tether’s action to freeze USDT assets is part of an ongoing regulatory process that involves potential amendments, review periods, and requests for comment from stakeholders. The outcome of such steps could influence future regulatory policies and the operational framework for stablecoins.

As the regulatory landscape continues to evolve, stakeholders within the crypto industry remain vigilant about compliance requirements and enforcement actions. The situation underscores the importance of regulatory clarity and the necessity for issuers to align their operations with legal mandates.

With no specific timeline disclosed for resolving the frozen assets’ status, market participants are watching closely for Tether’s next moves and any further regulatory guidance. The decision to freeze such a substantial amount highlights the balance stablecoin issuers must maintain between facilitating decentralized finance and adhering to centralized regulatory demands.

Post Views: 1

Ethereum continues to hold its bullish tone above $3K, backed by both technical breakouts and renewed on-chain strength. This resilience comes at a time when Bitcoin remains the center of attention due to macro and geopolitical events, ranging from rising tensions in the Middle East to financial instability across emerging markets.

Ethereum Price Analysis: The Daily Chart The daily structure shows that ETH has broken out of its descending parallel channel, flipping the $3K zone into strong support. The price recently tapped into the major resistance zone between $3.3K–$3.7K but faced selling pressure, printing a few consecutive bearish candles. This zone overlaps with both the 100-day and 200-day moving averages, creating a technical barrier that bulls must reclaim for continuation.

Despite the rejection, the RSI remains in healthy territory, currently pulling back from overbought levels. A potential higher low near the $3K range could serve as a bullish springboard. The key daily trendline also remains intact, and if the price maintains structure above the $2.7K zone, the bullish outlook remains valid. But reclaiming the $3.5K resistance level is now crucial to invalidate the local top.

ETH/USDT 4-Hour Chart On the 4-hour chart, ETH is consolidating just above the previous breakout zone around $3K, forming a potential base after its impulsive rally last week. The asset is respecting the $3K level, while the upper descending trendline capped the last move at around $3.3K. The current range between $3K–$3.1K is now acting as a mid-range value area and decision zone.

If buyers can push through the $3.3K level, it opens the door for a retest of the $3.5K level and possibly a breakout toward $4K. However, if the price falls below $3K with volume, the market could revisit the lower boundary of the pattern near $2.9K and even the high-confluence demand area lower at $2.6K. So far, the structure still favors the buyers, but caution is warranted in the short term.

Onchain Analysis Ethereum’s 30-day SMA of active addresses is trending higher again, following a significant dip in Q3–Q4 2025. Historically, rising address activity often precedes or coincides with sustainable price rallies, and the latest uptick is no exception. As of now, active addresses are hovering above 400K, mirroring levels seen during the last major uptrend.

This bounce suggests improving network fundamentals, potentially driven by increased DeFi activity and restaking flows. If this on-chain momentum continues and active addresses increase even more, it would provide strong confirmation of sustained demand, reinforcing Ethereum’s medium-term bullish case.

Tags:

Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure

Charles Hoskinson used a January 9, 2026 video update to outline an aggressive 2026 push that aims to turn Cardano’s DeFi stack into a cross-ecosystem product, explicitly targeting Bitcoin and XRP DeFi integrations alongside Midnight, new bridges, expanded oracle coverage, stablecoin work, and a faster cadence of ecosystem delivery.

2026 Is a Defining Year For Cardano Broadcasting from Colorado, Hoskinson framed the year as an execution cycle, with Cardano’s “Pentad” integrations effort positioned as the on-ramp for liquidity, users, and what he described as “commercially critical” infrastructure. He said contract signings slowed during the holidays, but insisted the deals were still in motion and would feed into near-term announcements around “bridges and more oracles and stablecoins and analytics,” as well as “more listings.”

The core thesis of Hoskinson’s update was that Cardano can’t win a marginal arms race against other smart contract platforms, and instead needs differentiated features and distribution through interoperability. In his telling, the Pentad structure is meant to ensure Cardano “is no longer an island,” enabling liquidity and users to “flow freely,” and setting up what he called the “next stage after pentad phase one.”

That next stage, Hoskinson said, should focus on upgrading Cardano’s most important applications to reach beyond the chain’s current boundaries. “I’m going to propose that we take the top 15 dabs top 20 dapps we got to figure out a list on Cardano and get them sons of ***** upgraded to Bitcoin DeFi, XRP DeFi and Midnight and also get them tier one listings, get them aboard, get them incubated, accelerated so we can 10x their TVL, their users and their transaction volume,” he said.

He framed this as both an internal ecosystem support plan and a growth strategy built around bringing Cardano-native apps to where large pools of capital and users already sit.

Hoskinson repeatedly returned to privacy, positioning it as the “new experiences” Cardano can ship rather than competing on incremental improvements. He argued that Cardano DeFi won’t be competitive “by being slightly better, slightly faster, slightly cheaper than Ethereum or Solana,” and said copycat strategies fail.

“You beat those guys by doing something that no one’s ever seen before,” he said, before laying out the product concept in unusually direct terms. “And when you add privacy and get private stablecoins, that’s going to be sexy. Show private prediction markets, private DEXes, you’re bringing something new to the conversation. You’re bringing something new to the table, something that people haven’t seen before.”

In Hoskinson’s framing, the pitch is not just privacy on Cardano, but portability of those capabilities across ecosystems once the bridge and stablecoin plumbing is in place, naming Solana, Ethereum, Bitcoin, XRP, BNB, and Avalanche as targets for that distribution.

Happy New Year https://t.co/P3GXCCQdzV

— Charles Hoskinson (@IOHK_Charles) January 10, 2026

2025 Frustration, 2026 Cadence Hoskinson also used the update to vent about industry expectations and what he called unmet promises from US policy narratives in 2025, arguing the sector needs to refocus on adoption and delivery rather than waiting for validation. He described 2026 as “our year,” and pointed to a schedule of near-term public-facing moments: workshops, a Japan tour, and Consensus Hong Kong where he said Cardano will show “some amazing announcements and special surprises.”

He also previewed a more regimented output rhythm. “And then, the rest of the year, every two months, a bag of goodies comes. That’s the cadence,” Hoskinson said, characterizing it as a “death march” of shipping.

At press time, ADA traded at $0.3953.

ADA hovers below key resistance, 1-week chart | Source: ADAUSDT on TradingView.com Featured image created with DALL.E, chart from TradingView.com

Editorial Process for bitcoinist is centered on delivering thoroughly researched, accurate, and unbiased content. We uphold strict sourcing standards, and each page undergoes diligent review by our team of top technology experts and seasoned editors. This process ensures the integrity, relevance, and value of our content for our readers.

President Donald Trump has reiterated that US companies will invest at least “$100 billion” to rebuild Venezuela’s energy sector under American security guarantees.

Yet major oil chief executives stopped short of committing to a rapid return as they met with the US President over the weekend.

In fact, Exxon’s leader, Darren Woods, even went to the extent of calling Venezuela “uninvestable”.

Still, the Energy Select Sector SPDR Fund (XLE) has inched higher in recent sessions – reflecting investors’ belief that the Venezuela episode means more opportunity than risk for oil stocks.

Exxon CEO explains why Venezuela isn’t exciting to invest Copy link to section

Exxon executive Darren Woods was blunt in his assessment of Venezuela’s investment climate.

He reminded Trump that Venezuela has seized XOM’s assets twice in the past – leaving the giant with billions in unresolved arbitration claims.

“If we look at the legal and commercial constructs and framework in place in Venezuela today, it’s uninvestable,” Woods added.

“We have had our assets seized there twice, and so you can imagine to re-enter a third time would require some pretty significant changes from what we’ve historically seen here.”

According to him, Exxon is willing to send a technical team to evaluate the state of Venezuela oil infrastructure, but Woods emphasized that without fundamental reforms, the company can’t justify re-entry.

What needs to change in Venezuela to attract investment Copy link to section

Executives from other major US energy companies echoed similar concerns.

For example, Ryan Lance – the chief executive of ConocoPhillips – congratulated President Trump on political changes but stressed that Venezuela’s debt burden and broken financial system must also be addressed.

He believes the banking sector will need to restructure billions in obligations to restore credibility.

Lance also called for a complete overhaul of state‑owned Petróleos de Venezuela – saying, “As we think that big and bold, we need to be also thinking about even restructuring the entire Venezuelan energy system including PDVSA.”

Chevron, which still operates a joint venture in Venezuela, noted it could double liftings immediately and expand production by 50% within two years – but even its cautious optimism underscored the need for disciplined investment frameworks.

What to expect from US oil stocks in 2026 Copy link to section

For US oil stocks, the Venezuela debate highlights both opportunity and risk.

On one hand, access to the country’s vast reserves could provide majors with long‑term growth if reforms materialize. On the other hand, hesitation from Exxon and Conoco shows that investors should not expect quick gains.

Treasury Secretary Scott Bessent suggested smaller independents and wildcatters may move faster, noting, “The big oil companies who move slowly, who have corporate boards, are not interested.”

That dynamic could shift capital flows toward nimble players rather than established giants.

In 2026, US oil stocks remain supported by strong domestic production and disciplined capital spending – but Venezuela’s uncertain path means Wall Street will treat all announcements with caution.

A drone view shows oil tankers loading crude oil at the Basra Oil Terminal in Iraqi territorial waters, off the coast of Basra, Iraq, August 5, 2025. REUTERS/Mohammed Aty Purchase Licensing Rights, opens new tab

CompaniesJan 12 (Reuters) - Oil prices are likely to drift lower this year as a wave of supply creates a market surplus, although geopolitical risks tied to Russia, Venezuela and Iran will continue to drive volatility, Goldman Sachs said in a note on Sunday.

The investment bank maintained its 2026 average price forecasts of $56/$52 per barrel for Brent/WTI, and expects Brent/WTI prices to bottom at $54/50 in the last quarter as OECD inventories build up.

Sign up here.

"Rising global oil stocks and our forecast of a 2.3mb/d surplus in 2026 suggest that rebalancing the market likely requires lower oil prices in 2026 to slow down non-OPEC supply growth and support solid demand growth, barring large supply disruptions or OPEC production cuts," Goldman Sachs said.

Brent crude futures were trading around $63 a barrel, as of 0412 GMT, while U.S. West Texas Intermediate crude holds ground at $59. Last year, both the benchmarks posted their worst annual performance since 2020, with an almost 20% decline.

U.S. policymakers' focus on strong energy supply and relatively low oil prices will keep sustained oil price upside in check ahead of the midterms, analysts at the bank noted.

Prices are expected to gradually start recovering in 2027, with the market returning to a deficit as non-OPEC supply slows down and solid demand growth continues, Goldman analysts said in a note.

The investment bank expects Brent/WTI to average at $58/54 in 2027, although $5 lower than its prior estimate, citing upgrades to 2027 supply in the U.S., Venezuela and Russia by 0.3, 0.4 and 0.5mb/d, respectively.

Goldman said it expects a substantial price recovery later this decade as demand grows through 2040 after years of low long-cycle investment, with 2030–2035 Brent/WTI prices averaging $75/$71, $5 below its previous estimate.

Risks to the price forecasts are skewed modestly to the downside given a further increase in non-OPEC supply, Goldman said, adding that it expects no OPEC production cuts, despite geopolitical risks and low speculative positioning.

"We still recommend investors short the 2026Q3-Dec2028 Brent time-spread to express the 2026 surplus view, and oil producers hedge 2026 price downside."

Reporting by Swati Verma in Bengaluru; Editing by Sherry Jacob-Phillips

Our Standards: The Thomson Reuters Trust Principles., opens new tab

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Mattel, Inc. (NASDAQ: MAT) unveiled today its first-ever autistic Barbie doll created with guidance from the autistic community to represent common ways autistic people may experience, process, and communicate about the world around them. This doll invites more children to see themselves represented in Barbie. Developed for more than 18 months in partnership with ASAN, a non-profit disability rights organization run by and for autistic people that advocates.

By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Trump said he wants to leave Exxon out of Venezuela. SAUL LOEB / AFP via Getty Images 2026-01-12T05:02:01.216Z

Trump said he wants to keep ExxonMobil out of Venezuela, saying it was "playing too cute." Exxon CEO Darren Woods said on Friday that Venezuela is currently "uninvestable." Other oil companies, like Chevron, pledged a commitment to increase oil production in Venezuela. President Donald Trump said he's "inclined" to keep ExxonMobil out of Venezuela.

In a Sunday press gaggle on Air Force One, a reporter asked Trump which oil companies have made commitments to investments in Venezuela, and if Exxon has done so.

"I'd probably be inclined to keep Exxon out. I didn't like their response. They're playing too cute," Trump said to the reporter.

He said that he did not like Exxon's response to his $100 billion plan to invest in the Venezuelan oil industry. On Friday, Exxon's CEO, Darren Woods, told the president that he does not think Venezuela is currently ripe for investment.

"If we look at the legal and commercial constructs and frameworks in place today in Venezuela — today, it's uninvestable," Woods said in the meeting with Trump and oil executives at the White House.

He said that Exxon, which is based in Texas, has a long history in Venezuela, having operated in the country twice. He said the company has had its assets in Venezuela seized on both those occasions.

Woods said that significant changes need to happen in the country to consider reentering, but he was confident the Trump administration could work with the Venezuelan government to implement those changes.

However, other oil executives were more optimistic. Chevron's vice chairman, Mark Nelson, told Trump that the company plans to increase its current production with oil partners in Venezuela by 100% "effective immediately."

Trump's comments about Exxon come more than a week after US military forces launched a strike in Venezuela and captured the Venezuelan President Nicolás Maduro and his wife. Maduro is being tried by a New York court for drug trafficking and weapons charges.

Exxon's stock price has remained largely flat after the bell on Friday. It's up more than 16% in the past year.

Trump

Read next

In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying effectThe company is working with health authorities to find the optimal pathway to approval Allschwil, Switzerland – January 12, 2026
Idorsia Ltd (SIX: IDIA) announces the publication of results from the pivotal Phase 3 MODIFY study and its open-label extension (OLE) evaluating lucerastat, an oral substrate reduction therapy, in adults with Fabry disease. The data, published in Nature Communications, titled “Lucerastat, an oral therapy for Fabry disease: Results from a pivotal phase 3 study and its open-label extension”, reinforce lucerastat’s potential to address key unmet needs in Fabry disease, particularly in patients with renal impairment.

About the MODIFY study (NCT03425539) and its open label extension (NCT03737214)
MODIFY was a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat as an oral monotherapy in adult patients with Fabry disease. 118 patients were randomized in a 2:1 ratio to either lucerastat or placebo. At the end of the double-blind period, 107 patients entered an open label extension study, to determine the long-term safety and tolerability of lucerastat oral therapy and to further evaluate its clinical efficacy on renal function, in adult patients with Fabry disease.

The MODIFY study in Fabry disease enrolled a diverse population of 118 patients across 14 countries. As announced in an earlier press release, while the study did not meet its primary endpoint of reducing neuropathic pain over six months, lucerastat demonstrated a robust pharmacodynamic effect, significantly reducing plasma and urinary Gb3 levels compared to placebo. These reductions were sustained over time in the OLE, with patients switching from placebo to lucerastat showing similar biomarker reductions.

More importantly, an interim analysis of the OLE, where ongoing patients had been treated with lucerastat for at least 12 months, revealed a notable shift in renal function trajectory, with a reduction in the rate of eGFR decline among patients treated with lucerastat as compared to eGFR slope observed in the 2 years preceding their enrollment in MODIFY. In patients with impaired renal function or fast-deteriorating eGFR at baseline, lucerastat was associated with a marked attenuation of kidney function loss, suggesting a potential disease-modifying effect. In addition, there was a stabilization of cardiac function, with no worsening over time of the echocardiography left ventricular mass index (see this press release for more details).

Professor Derralynn Hughes, University College London, Royal Free London NHS Foundation Trust, London, UK, Chief Investigator in MODIFY commented:
“Stability or the reduction of loss of kidney function is a therapeutic goal for patients with Fabry disease. This can only be seen with long-term treatment. The renal signal observed in the long-term evaluations is encouraging and warrants further investigation. Lucerastat’s oral administration, tolerability, and mechanism make it an important candidate for broader Fabry disease populations.”

Beyond the reported interim analysis, the OLE has now collected data from patients who continued treatment with lucerastat for at least 42 months, with some treated with lucerastat for over 6 years. Lucerastat was well tolerated, with no treatment-related serious adverse events. In addition, Idorsia has conducted a kidney biopsy sub-study belonging to the OLE of the Phase 3 study. This sub-study enrolled male participants with classic Fabry disease who had been treated for more than 3 years with lucerastat monotherapy. The main objective of the sub-study was to evaluate the number of Gb3 inclusions in certain types of kidney cells using established methods of quantification.

The data collected in such a small population are very encouraging, support further investigation for patients with Fabry disease, and have been instrumental in the design of a new Phase 3 program. The company is working with the US FDA to design the optimal program to ensure the regulatory pathway to approval.

As the next steps for lucerastat are being planned, the OLE study will be concluded. To ensure continuity of care for participants still receiving lucerastat at study closure, a post-trial access program is being established.

Alberto Gimona MD, Head of Global Clinical Development at Idorsia, commented:
“The patients who have taken part in MODIFY and the extension study – some of whom have now been treated with lucerastat for over 6 years – have been true heroes for the Fabry community. Thanks to their participation, we have gained great insight into the benefits of long-term treatment with lucerastat. The data reported in Nature Communication, together with the confirmatory results from the longer treatment duration and the kidney biopsy sub-study, are driving us to generate the regulatory data required to bring lucerastat to patients. We remain committed to advancing this innovative treatment for patients living with Fabry disease.”

Notes to the editor

About Fabry disease
Fabry disease is a rare, X-linked lysosomal storage disorder caused by mutations in the GLA gene, resulting in deficient or absent activity of the enzyme α-galactosidase A (α-Gal A). This enzymatic deficiency leads to the accumulation of globotriaosylceramide (Gb3) and its derivatives in cells throughout the body. Over time, this buildup causes progressive damage across multiple organ systems, including the kidneys, heart, nervous system, skin, eyes, and gastrointestinal tract.

The disease manifests in two main phenotypes: classic Fabry disease, typically presenting in childhood with severe, multisystemic involvement, and late-onset Fabry disease, which may emerge in adulthood with predominant cardiac or renal symptoms. Due to its variable presentation and non-specific symptoms, Fabry disease is frequently underdiagnosed or misdiagnosed, leading to delays in treatment and increased risk of irreversible organ damage.

Recent newborn screening programs and high-risk population studies suggest that Fabry disease is more prevalent than previously estimated, with a diagnosed prevalence of more than 21,000 patients expected across the US, EU5, and Japan by 2034, and a higher incidence of late-onset forms. Notably, female patients, once considered carriers, are now recognized as affected individuals with a wide spectrum of disease severity – up to 70% of heterozygous females develop Fabry-related symptoms during their lifetime.

Current treatment options include enzyme replacement therapies (ERTs) and oral chaperone therapy for patients with amenable mutations. However, these therapies have limitations, including intravenous administration, immunogenicity, and mutation-specific efficacy. There remains a significant unmet need for a well-tolerated, oral, disease-modifying therapy that can be used regardless of genotype or prior treatment history.

Lucerastat in Fabry disease
Lucerastat is an investigational, oral substrate reduction therapy designed to treat Fabry disease independently of α-Gal A activity, GLA mutation status, or prior enzyme replacement therapy (ERT). It acts by inhibiting glucosylceramide synthase, thereby reducing the synthesis of glycosphingolipids, including globotriaosylceramide (Gb3), which accumulate due to deficient α-galactosidase A activity in Fabry disease.

Preclinical studies demonstrated that lucerastat is a highly soluble and bioavailable small molecule capable of penetrating key tissues affected by Fabry disease – including the kidneys, liver, and dorsal root ganglia – where it effectively reduces substrate accumulation. Clinical pharmacology studies confirmed lucerastat’s favorable pharmacokinetic profile, characterized by rapid absorption, predictable elimination, and no evidence of saturation, supporting consistent exposure across dosing regimens.

In early clinical trials, lucerastat was well tolerated at doses up to 4000 mg, with no dose-limiting toxicities and a safety profile unaffected by concomitant medications. In a 12-week exploratory study in adult Fabry patients receiving ERT, lucerastat 1000 mg twice daily led to a rapid and sustained reduction in plasma Gb3 and related biomarkers, confirming its mechanism of action and potential for fast-onset substrate reduction.

The recently published Phase 3 MODIFY study and its long-term extension further support lucerastat’s disease-modifying potential. While the primary endpoint of neuropathic pain reduction was not met, lucerastat demonstrated robust and sustained biomarker reductions and a promising renal signal, with a slower rate of eGFR decline in patients with impaired kidney function. These findings suggest lucerastat may offer long-term organ protection and broaden therapeutic options for Fabry patients, especially those underserved by current treatments.

About Prof Derralynn Hughes
Prof Derralynn Hughes is professor of experimental hematology at the University College London, director of research and innovation at the Royal Free London, and co-clinical director of the North Central London Cancer Alliance. Prof Hughes is also chair of the international working group on Gaucher disease. She has clinical responsibilities in the area of hematology and lysosomal storage disorders (LSD) and is chair of the anemia clinical practice group.

Prof Hughes directs the research program in the LSD unit where interests include understanding the pathophysiology of phenotypic heterogeneity in Fabry disease and bone-related pathology in Gaucher disease and malignancy. Prof Hughes is principal investigator of a number of clinical trials examining the efficacy of enzyme, chaperone and gene therapies and other new agents in the treatment of Gaucher, Fabry, Pompe and MPS disorders. A particular interest relates to the clinical and biological effects of bone disease and malignancy in Gaucher disease. She is an author of over 150 papers in the area of macrophage biology and lysosomal storage disorders. Prof Hughes serves as a consultant to Idorsia.

Key scientific literature

Nordbeck P., et al. Lucerastat, an oral therapy for Fabry disease: Results from a pivotal phase 3 study and its open-label extension. Nature Communications, 10 January 2026 (online ahead of print). https://doi.org/10.1038/s41467-025-68256-5Guérard N., et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther. 2018; 103(4):703-11.Welford RWD., et al. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types. Hum Mol Genet 2018; 27(19): 3392-3403Germain DP. Fabry disease. Orphanet J Rare Dis. 2010 Nov 22;5:30. About Idorsia
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.

Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).

For further information, please contact:
Investor & Media Relations
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
[email protected] – [email protected] – www.idorsia.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs, business development activities and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

Press Release PDF

January 12, 2026 01:00 ET  | Source: argenx SE

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales

VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026

Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches

Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contributing to total of 10 clinical-stage molecules by year-end

January 12, 2026, 7:00 a.m. CET

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported preliminary financial results for the full-year 2025, including global product net sales, and announced its strategic priorities for 2026.

“argenx enters 2026 in a position of strength, delivering meaningful impact to approximately 19,000 patients globally while advancing a world-class pipeline toward Vision 2030,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx. “With VYVGART leading the growth of all biologics in MG and CIDP, we are proving the power of our approach: to redefine treatment paradigms through disciplined evidence generation and to redefine patient outcomes with medicines that are both more effective and more convenient. This same playbook will guide our future, as we aim to launch a portfolio of new medicines that could transform the lives of more than 50,000 patients across 10 indications.”

“Looking at the year ahead, we will expand our FcRn franchise and report the first Phase 3 data for our next potential blockbuster medicine, with four registrational readouts across both efgartigimod and empasiprubart. In addition, we will continue to grow intentionally, by sourcing innovation where the best science emerges, nurturing an entrepreneurial culture, and scaling with discipline to deliver long-term, durable value for patients and shareholders,” added Mr. Van Hauwermeiren.

2026 Strategic Priorities

argenx continues to advance its ‘Vision 2030’, anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications across approved medicines, and progress five pipeline candidates into Phase 3 development by 2030.

2026 marks a defining year on the path to Vision 2030 with three strategic priorities:

Impact more patients globally with VYVGART, driving broader adoption across current patient populations and unlocking new opportunities with potential label expansionsShape the long-term future of FcRn medicines, advancing future FcRn molecules, innovative delivery modalities and combination approaches designed to transform patient outcomesDeliver next wave of immunology innovation, accelerating empasiprubart and diversified pipeline of first-in-class molecules to drive sustainable value creation Impact more patients globally with VYVGART

VYVGART® (IV: efgartigimod alfa-fcab and SC: efgartigimod alfa and hyaluronidase-qvfc) is a first-and-only IgG Fc-antibody fragment that targets the neonatal Fc receptor (FcRn). It is approved in three indications, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) globally, and primary immune thrombocytopenia (ITP) in Japan. argenx aims to drive broad adoption across patients globally, reinforcing VYVGART’s position as the leading precision biologic in MG and CIDP and continuing to raise the bar for patient outcomes. The company is progressing toward multiple label expansions. This includes seeking the broadest label of any biologic in MG with the seronegative MG launch, if approved, and an ocular MG Phase 3 readout, and in ITP with the Phase 3 readout to support a U.S. launch.

Submitted supplemental Biologics License Application (sBLA) for VYVGART IV for anti-acetylcholine receptor antibody negative gMG (MuSK+, LRP4+ and triple seronegative); if approved, launch expected by end of 2026Topline results expected for ocular MG (ADAPT OCULUS) in first quarter of 2026Topline results expected for primary ITP (ADVANCE-NEXT) in fourth quarter of 2026Registrational studies are ongoing in two rheumatology indications Topline results from ALKIVIA study evaluating autoimmune inflammatory myopathies (AIM or myositis) expected in third quarter of 2026Topline results from UNITY study (Sjogren’s disease) expected in second half of 2027 Registrational study in Graves’ disease (GD) expected to initiate in 2026, expanding development into thyroid-driven autoimmunityProof-of-concept studies ongoing in systemic sclerosis, antibody mediated rejection and autoimmune encephalitisExpanded global presence in Latin America with establishment of argenx Brazil in 2025 Shape the long-term future of FcRn medicines

argenx is shaping the long-term future of FcRn medicines by advancing new pipeline candidates, innovative delivery modalities, and combination approaches to set new standards for patients. Two future FcRn molecules are progressing: ARGX-213, an FcRn-targeted antibody engineered for half-life extension and sustained IgG reduction, and ARGX-124, a first-in-class FcRn pipeline candidate. The ADAPT-Forward study is now underway, which is the first in a series of trials exploring efgartigimod-anchored combinations to potentially improve patient outcomes.

VYVGART SC autoinjector expected to launch in 2027, reinforcing a commitment to continued flexibility and independence for patientsADAPT-Forward combination study ongoing to evaluate empasiprubart as an add‑on therapy to efgartigimod, exploring potential for even deeper efficacy in AChR‑positive gMG patientsARGX-213 is expected to enter patient studies in 2026ARGX-124 is expected to complete Phase 1 evaluation by end of 2026Innovation in FcRn continues through partnerships with Elektrofi (now part of Halozyme) and Unnatural Products to further enhance the patient experience Deliver next wave of immunology innovation

By the end of 2026, the argenx pipeline will include four Phase 3 molecules and a total of 10 molecules in clinical development. Empasiprubart, a first-in-class antibody targeting C2, is in Phase 3 for MMN and CIDP, and adimanebart (ARGX-119), a first-in-class agonist antibody targeting muscle-specific kinase (MuSK), will enter Phase 3 for congenital myasthenic syndromes (CMS). Additional proof-of-concept studies are underway to further explore C2 and MuSK biology. In 2025, four new candidates emerged from the Immunology Innovation Program (IIP), argenx’s engine for sourcing novel biology and accelerating differentiated medicines. These include FcRn candidates ARGX-213 and ARGX-124, and ARGX-109 (targeting IL-6) and ARGX-121 (a first-in-class molecule targeting IgA). Three additional molecules from the IIP are expected to enter Phase 1 in 2026, supporting argenx’s goal of launching, on average, one new pipeline candidate each year.

Empasiprubart

Topline results from EMPASSION study (MMN) expected in fourth quarter of 2026Topline results from EMVIGORATE and EMNERGIZE studies (CIDP) expected in second half of 2027Decision for Phase 2 VARVARA study (DGF) now expected mid-year 2026 to complete 52-week efficacy analysis Adimanebart

CMS registrational study on track to start in third quarter of 2026Proof-of-concept studies ongoing in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) Earlier-stage Programs

Phase 2 study of ARGX-121 in IgA nephropathy (IgAN) expected to start in 2026Entered into a research collaboration with Tensegrity Pharma, including an option for future acquisition, to advance Tensegrity’s lead program TSP-101 in autoimmune disease and other indications.Three new molecules expected to enter Phase 1 studies in 2026, including ARGX-118, a first-in-class molecule targeting Galectin-10, ARGX-125, a first-in-class bispecific antibody, and TSP-101, targeting Fn14 Corporate Highlights
argenx recently announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and Executive Director, and Tim Van Hauwermeiren, current Chief Executive Officer, will transition to non-Executive Director and Chairman of the Board of Directors. Tim will succeed Peter Verhaeghe, who is retiring from the Board of Directors. These changes are subject to shareholder approval at the Annual General Meeting on May 6, 2026.

In addition, Sandrine Piret-Gérard has been appointed Chief Commercialization Officer. Sandrine brings extensive commercial and medical affairs experience, most recently leading the U.S. commercial organization at Gilead across virology and oncology.

Preliminary* Key Fourth Quarter and Full-Year 2025 Financial Results
Today, argenx also announced preliminary* global product net sales for the fourth quarter and full-year 2025 of approximately $1.29 billion and $4.15 billion, respectively.

*The preliminary selected financial information is unaudited, subject to adjustment, and provided as an approximation in advance of the company’s announcement of complete financial results in February 2026. Refer to the Preliminary Financial Results note in this document.

44th Annual J.P. Morgan Healthcare Conference Presentation and Webcast

CEO Tim Van Hauwermeiren will highlight these updates in a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference today, Monday, January 12, 2026, at 8:15 a.m. PT. The live webcast of the presentation may be accessed under the Investor section on the argenx website. A replay will be available for 30 days following the presentation.

About VYVGART and VYVGART SC

VYVGART® (efgartigimod alfa fcab) is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG autoantibodies. It is the first approved FcRn blocker for the treatment of generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) globally, and for primary immune thrombocytopenia (ITP) in Japan. VYVGART SC is a subcutaneous combination of efgartigimod alfa and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous injection delivery of biologics. It is marketed as VYVGART® Hytrulo in the U.S., VYVGART SC in Europe, VYVDURA® in Japan, and may be marketed under different proprietary names following approval in other regions.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit  www.argenx.com  and follow us on LinkedIn, Instagram, Facebook, and YouTube.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (Regulation 596/2014).

Media:
Ben Petok
[email protected]

Investors:
Alexandra Roy
[email protected]

Preliminary Financial Results

The financial information presented in this press release is preliminary, estimated, and unaudited. They are subject to the completion and finalization of argenx’s financial and accounting closing procedures. They reflect management’s estimates based solely upon information available to management as of the date of this press release. Further information learned during that completion and finalization may alter the final results. In addition, the preliminary estimates should not be viewed as a substitute for full quarterly and annual financial statements prepared in accordance with IFRS. There is a possibility that argenx’s financial results for the quarter ended December 31, 2025, and full year financial results for 2025 could vary materially from these preliminary estimates. In addition to the completion of the financial closing procedures, factors that could cause actual results to differ from those described above are set forth below. Accordingly, you should not place undue reliance upon this preliminary information. Additional information regarding the company’s fourth quarter 2025 financial results and full year financial results for 2025 will be available in the company’s annual report and Form 20-F, which will be filed with the Netherlands Authority for the Financial Markets and U.S. Securities and Exchange Commission (the “SEC”), respectively.

Forward Looking Statements
The contents of this announcement include statements that are, or may be deemed to be, “forward-looking statements.” These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “advance,” “aim,” “commit,” “continue,” “deepen,” “develop,” “expect,” “grow,” “potential,” “progress,” and “will,” and include statements argenx makes concerning its continued impact of VYVGART and if approved, the potential launch of AChR-Ab seronegative gMG launch by end of 2026; its four registrational readouts expected in 2026 to advance efgartigimod and empasiprubart towards next wave of 2027 commercial launches; the advancement of its pipeline, with three new molecules to enter Phase 1 in 2026, contributing to total of 10 clinical-stage molecules by year-end; its advancement of a world-class pipeline toward Vision 2030; its continued advancement of Vision 2030, anchored in the ambition to treat 50,000 patients globally with its medicines, secure 10 labeled indications across approved medicines, and progress five pipeline candidates into Phase 3 development by 2030; its intentional growth by sourcing innovation where the best science emerges, preserving its entrepreneurial culture, and scaling with discipline to deliver long-term, durable value for patients and shareholders; its belief that 2026 will be a defining year that will deepen its immunology leadership and broaden patient impact, including its goal to impact more patients globally with VYVGART by driving broader adoption across current patient populations while unlocking new opportunities through potential label expansions; the timing of a potential (1) launch in AChR- seronegative MG, and (2) Phase 3 readouts in ocular MG and ITP; the advancement of anticipated clinical development, data readouts and regulator milestones and plans, including: (1) the potential approval and launch by the end of 2026 of an sBLA for VYVGART IV for anti-acetylcholine receptor antibody negative gMG (MuSK+, LRP4+ and triple seronegative; (2) topline results for ocular MG (ADAPT OCULUS) in first quarter of 2026; (3) topline results for primary ITP (ADVANCE-NEXT) in fourth quarter of 2026 to support label expansion outside Japan; (4) ongoing registrational studies in two rheumatology indications, in Graves’ disease, and in multiple proof-of-concept indications, including: (a) potential topline results from ALKIVIA study evaluating autoimmune inflammatory myopathies (AIM or myositis) in third quarter of 2026; (b) potential topline results from UNITY study (Sjögren’s disease) in second half of 2027; (c) potential initiation of a registrational study in Graves’ disease (GD) in first half of 2026, expanding development into thyroid-driven autoimmunity; (5) broadened global presence in Latin America through establishment of argenx Brazil in 2025; the progression of ARGX-213 and ARGX-124; the progression of a series of trials exploring efgartigimod-anchored combinations to potentially improve patient outcomes, including: (1) the potential launch of VYVGART SC autoinjector in 2027; (2) the ongoing ADAPT-Forward combination study; (3) potential studies for ARGX-213 in 2026; (4) potential completion of ARGX-124’s Phase 1 evaluation by end of 2026; and (5) continued innovation in FcRn through partnerships with Elektrofi (now part of Halozyme) and Unnatural Products; its goal to have five Phase 3 molecules and a total of 10 molecules in clinical development by the end of 2026; the additional proof-of-concept studies underway to further explore the potential of C2 and MuSK biology, with: (1) potential topline results from EMPASSION study (MMN) for empasiprubart in fourth quarter of 2026; (2) potential topline results for empasiprubart from EMVIGORATE and EMNERGIZE studies (CIDP) in second half of 2027; (3) potential for decision for Phase 2 VARVARA study (DGF) for empasiprubart now mid-year 2026 to complete 52-week efficacy analysis; (4) potential for CMS registrational study for adimanebart to start in third quarter of 2026; and (5) proof-of-concept studies for adimanebart ongoing in amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA); its goal to launch at least one new pipeline candidate each year on a go-forward basis, with: (1) IgA nephropathy (IgAN) nominated as first Phase 2 indication to be explored with ARGX-121; (2) its research collaboration with Tensegrity Pharma; (3) the entry of three new molecules into its pipeline in 2026, including ARGX-118, ARGX-125, and TSP-101; its aim to shape the long-term future of FcRn medicines, and deliver the next wave of immunology innovation; its commitment to improve the lives of people suffering from severe autoimmune diseases; its belief that its priorities for VYVGART will reinforce its position as the leading precision biologic and continue to raise the bar on patient outcomes; its aim to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines; its commercialization of the first approved neonatal Fc receptor (FcRn) blocker and evaluation of its broad potential in multiple serious autoimmune diseases; its anticipated leadership changes; its future financial and operating performance, including its anticipated global product net sales for Q4 2025 and FY 2025; and its advancement of several earlier stage experimental medicines within its therapeutic franchises. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx’s clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

January 12, 2026 01:00 ET  | Source: Wisekey International Holding Ltd.

WISeKey, together with its Subsidiaries, WISeSat and SEALSQ, to Partner with Kaynes Technology’s Satellite Subsidiary KSTPL, to Manufacture Post-Quantum Secure WISeSats Satellites in India and Establish India as a Strategic Launch Hub

Geneva, Switzerland / Bengaluru, India: January 12, 2026 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its subsidiary, WISeSat.Space (“WISeSat”), a global leader in secure satellite and critical digital satellite infrastructure, signed a strategic cooperation agreement with Kaynes Technology India Limited (Kaynes Technology) satellite subsidiary Kaynes Space Technology Private Limited (“KSTPL”), to manufacture post-quantum-secure WISeSat satellites in India and establish India as one of its official satellite launch locations, in addition to its current launch operations in the United States.

This collaboration, which brings together two of WISeKey’s subsidiaries, WISeSat and SEALSQ Corp (NASDAQ: LAES) (“SEALSQ”) which focuses on semiconductors, PKI, and post-quantum technology products, along with KSTPL aims to create a new generation of quantum-resilient satellite infrastructure designed to protect global IoT connectivity against the emerging threats of quantum computing. Under the agreement, KSTPL will manufacture next-generation WISeSats in India, integrating SEALSQ’s post-quantum cryptographic semiconductor technology and WISeKey’s Root of Trust into each satellite, ensuring end-to-end security from orbit to ground and to billions of connected devices.

WISeSat and SEALSQ are preparing the launch of their next-generation post-quantum-hardened secure satellite in 2026. This upgraded WISeSat platform will serve as a testbed for post-quantum communication protocols directly from space, marking one of the first real-world demonstrations of quantum-resistant encryption operating in orbit. The mission represents a critical step toward enabling secure, sovereign, and future-proof satellite-based IoT networks capable of withstanding quantum-enabled cyberattacks.

By adding India as a strategic launch site alongside the United States, WISeSat gains access to India’s rapidly growing indigenous launch capabilities, strengthening operational resilience, geopolitical neutrality, and sovereign access to space. This multi-launch-site strategy ensures that the WISeSat constellation can be deployed, maintained, and expanded independently across multiple jurisdictions, reinforcing its role as a trusted infrastructure for governments, enterprises, and critical services worldwide.

KSTPL, incorporated in June 2025 as a wholly owned subsidiary of Kaynes Technology, was established with the purpose of designing, building, and launching satellites of all sizes, payloads, and indigenous launch vehicles, with a focus on cost-effective, sustainable space technologies for communication, defense, and Earth observation. KSTPL is developing modular satellite platforms, AI-based autonomy, propulsion systems, inter-satellite networks, and miniaturized payloads, and is building the full infrastructure required for launch operations, ground control, mission planning, and in-orbit servicing.

Through this partnership, KSTPL becomes a core manufacturing and launch partner for WISeSat’s post-quantum secure satellite constellation, placing India at the center of the world’s first industrialized quantum-resilient space network. The collaboration establishes a powerful new space-security corridor between Europe, India, and the United States, combining advanced semiconductor security, trusted digital identity, satellite engineering, and sovereign launch capability into a single integrated ecosystem.

“By working with KSTPL, we are bringing together India’s manufacturing excellence and space ambition with our post-quantum security and satellite technology,” said Carlos Creus Moreira, Founder and CEO of WISeKey. “This cooperation enables us to deliver highly secure, resilient satellite platforms at scale, while establishing a new global benchmark for secure space communications. Together, we are ensuring that the next generation of satellite-based IoT and connectivity services will be protected against both, today’s cyber threats and the emerging challenges of the quantum era.”

About WISeKey

WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform.

Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company’s semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.

Press and Investor Contacts

WISeKey International Holding Ltd
Company Contact: Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
[email protected] WISeKey Investor Relations (US) 
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
[email protected]

Sanofi’s Teizeild approved in the EU for patients with stage 2 type 1 diabetes

Approval based on the TN-10 phase 2 study that demonstrated a significant delay of onset of stage 3 T1D in stage 2 T1D patientsTeizeild represents a potential significant change in the treatment of autoimmune T1D, preventing the natural disease progression protecting beta-cell function Paris, January 12, 2026. The European Commission has approved Teizeild (teplizumab) to delay the onset of stage 3 type 1 diabetes (T1D) in adult and pediatric patients eight years of age and older with stage 2 T1D. This follows the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use. Teizeild is the first T1D disease-modifying therapy approved in the EU, marking a significant milestone in the treatment of this progressive autoimmune disease. The approval is based on positive results from the TN-10 phase 2 study (clinical study identifier: NCT01030861) demonstrating that Teizeild delayed the onset of stage 3 T1D by a median of two years compared to placebo, in adults and children aged eight years and older with stage 2 T1D.

“We are pleased that, for the first time, we will be able to offer patients and families in the EU a disease-modifying therapy designed to address the underlying immune process of type 1 diabetes,” said Olivier Charmeil, Executive Vice President, General Medicines, Sanofi. “We remain committed to working with external stakeholders across the EU to bring patients the benefits of Teizeild, a unique therapy that may prevent the natural progression of type 1 diabetes by protecting beta-cell function.”

At the end of the TN-10 phase 2 study, the proportion of patients who remained in stage 2 T1D was almost twice as high in the Teizeild group as in the placebo group (57% vs 28%). The safety profile was consistent with the one observed in previous studies of Teizeild. The most frequently observed adverse events were blood or bone marrow-related (transient lymphopenia) in 75% of the participants and dermatologic or skin-related (rash) in 36% of the participants.

Teizeild (known as Tzield outside the EU) is also approved in the US, the UK, China, Canada, Israel, the Kingdom of Saudi Arabia, the United Arab Emirates, and Kuwait to delay the onset of stage 3 T1D in adults and children aged eight years and older with stage 2 T1D. As previously communicated, following the positive CHMP recommendation for this newly approved indication, Sanofi has decided not to progress with a second application for Teizeild in recently diagnosed stage 3 T1D at this time. Next steps are under evaluation. Other regulatory reviews are ongoing.

About TN-10
The pivotal TN-10 phase 2 study was a randomized, placebo-controlled, double-blind study which evaluated Teizeild for the delay of stage 3 T1D in adults and children aged eight years and older diagnosed with stage 2 T1D (presence of at least two T1D-related autoantibodies and dysglycemia) who are relatives of people living with autoimmune T1D. Seventy-six participants aged eight to 45 were enrolled (Teizeild n=44, placebo n=32). They were randomized to receive a single 14-day course of either Teizeild or placebo.

The primary endpoint was the elapsed time from randomization to the clinical diagnosis of autoimmune stage 3 T1D (progression from stage 2 T1D to stage 3 T1D). Key secondary end points included safety and tolerability.

Results demonstrated that the median time to the diagnosis of stage 3 T1D was 48.4 months in the Teizeild group and 24.4 months in the placebo group. The disease was diagnosed in 19 (43%) of the participants who received Teizeild and in 23 (72%) of those who received placebo. The hazard ratio for the diagnosis of type 1 diabetes (Teizeild vs. placebo) was 0.41 (95% CI: 0.22 to 0.78; p=0.006 by adjusted Cox proportional-hazards model). There were expected adverse events of rash and transient lymphopenia. 

About Teizeild
Teizeild (teplizumab) is a CD3-directed monoclonal antibody. Teizeild is the first and only disease modifying therapy in autoimmune T1D; it was approved in the US in November 2022 to delay the onset of stage 3 type 1 diabetes in adults and children eight years and older diagnosed with stage 2 T1D. Today, it is also approved in the UK, China, Canada, Israel, the Kingdom of Saudi Arabia, the United Arab Emirates, and Kuwait for the same indication. Other regulatory reviews are ongoing.

About autoimmune T1D
T1D is a progressive autoimmune disease where the body’s ability to regulate blood sugar levels is impacted due to the gradual destruction of insulin producing beta cells by one’s own immune system. There are four stages to the progression of T1D:

In stage 1, the autoimmune attack to the beta cells has started, and this can be detected by the presence of 2 or more T1D-related autoantibodies in the blood. During stage 1, blood sugar levels are in a normal range (normoglycemia). At this stage, T1D is presymptomatic.In stage 2 (also presymptomatic), in addition to the presence of 2 or more T1D-related autoantibodies, blood sugar levels are now abnormal (dysglycemia) due to the progressive loss of beta cells / beta cell function.Stage 3 (also known as clinical stage) comes once a significant portion of the beta cells have been destroyed. At this point, rising blood sugar levels reach the point of clinical hyperglycemia (which defines diabetes), and many people will start to experience the classic symptoms that come with the onset of stage 3 T1D: increased thirst, frequent urination, unexplained weight loss, blurred vision, and generalized fatigue. Management of stage 3 T1D requires daily and burdensome insulin replacement therapy.Stage 4 is defined as long-standing autoimmune T1D, often accompanied by evidence of chronic diabetic complications, where little to no beta-cell function remains (it’s been estimated that beta-cell mass is reduced by up to 95%). At this point, the T1D-related autoantibodies might not be present anymore in the blood, as most beta-cells have been rendered useless by the autoimmune attack. About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.

Sanofi Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | [email protected]
Evan Berland | +1 215 432 0234 | [email protected]
Léo Le Bourhis | +33 6 75 06 43 81 | [email protected]
Victor Rouault | +1 617 356 4751 | [email protected]
Timothy Gilbert | +1 516 521 2929 | [email protected]
Léa Ubaldi | +33 6 30 19 66 46 | [email protected]
Ekaterina Pesheva | + 1 410 926 6780 [email protected] 

Sanofi forward-looking statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”, and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

All trademarks mentioned in this press release are the property of the Sanofi group.

Press_Release

“Building and using crypto infrastructure. Updating our global financial plumbing, and rethinking legacy systems – none of this happens overnight. At Ripple, we’re going to continue taking the long view of what crypto-based assets – like XRP and RLUSD – can do, rather than chasing cycles and hype. Bring on 2026. We are firing on all cylinders. It’s happening!”

Ripple Senior Executive Officer / Managing Director, Middle East & Africa, Reece Merrick, underpinned Garlinghouse’s message, stating:

“It’s hard to describe the energy at Ripple right now. 2025 was foundational, but with the acquisitions made, and now the UK EMI license in the mix, 2026 is looking like a total game changer.”

XRP-Spot ETFs Demand Underscores Positive Outlook Ripple’s strides onto Main Street and XRP’s central role have bolstered demand for XRP-spot ETFs, tilting the supply-demand balance in XRP’s favor.

The US XRP-spot ETF market has seen $1.22 billion in net inflows since its launch in mid-2025. According to SoSo Value, the Canary XRP ETF continued to dominate, with $393.66 million in net inflows, benefiting from a first-to-market advantage. Nevertheless, Bitwise XRP ETF (XRP), Franklin XRP ETF (XRPZ), and Grayscale XRP ETF (GXRP) have also seen strong demand.

However, 21Shares XRP ETF (TOXR), the newest of the spot ETFs, reported net outflows of $7.77 million since launch, potentially delaying filings for new XRP-spot ETFs.

SOSOValue – XRP-Spot ETF Market Flows XRP Decoupling Underway Despite ETF Issuer Activity Notably, WisdomTree withdrew its S-1 for an XRP-spot ETF last week, while Morgan Stanley filed S-1s for BTC-spot and SOL-spot ETFs. The ETF issuers’ stance on XRP came despite the XRP-spot ETF market outperforming the US BTC-spot and SOL-spot ETF markets.

For context, the US SOL-spot ETF market reported $816.92 million in net inflows since the October launch. Meanwhile, the US BTC-spot ETF market saw net outflows of $2.94 billion since the Canary XRP ETF launched on November 14.

Canary Funds CEO Steve McClurg expects XRP to diverge from BTC and the broader crypto market in 2026, stating:

“XRP, I believe, is going to be a divergent asset, actually. […] Altcoins typically follow Bitcoin, but there are a handful of assets that I do believe will diverge in this manner and just watching XRP perform as everything’s going straight down and we continue to get inflows every day and continue to hold up, I believe that it could look like another peak in XRP in 2026, when most of other crypto assets are going to be down.”

Notably, crypto market price trends in early 2026 suggest an XRP decoupling is already underway. While XRP has risen 11.5% year-to-date, BTC has gained 4.51%, while the total crypto market cap has increased 5.15%.

Increased XRP utility, strong demand for XRP-spot ETFs, and the Market Structure Bill’s progress on Capitol Hill continue supporting a cautiously bullish short-term (1-4 weeks) and bullish medium-term (4-8 weeks) price outlook.

Market Structure Bill Crucial for XRP Demand While XRP-spot ETF demand and XRP utility are crucial for XRP’s price outlook, the Market Structure Bill’s progress on Capitol Hill remains key.

This week, the market focus will be on the US Senate Banking Committee’s January 15 Market Structure Bill markup. XRP remains highly sensitive to crypto-related regulatory developments, given the resolution of the SEC vs. Ripple case in August 2025.

Over the weekend, the US Senate Banking Committee fueled optimism over the Market Structure Bill, stating:

“Chairman Senator Tim Scott is moving forward on digital asset market structure legislation – delivering clear rules that protect Main Street, keep innovation here at home, and safeguard US national security.”

The approved draft text from the US Senate Banking Committee would shift the market focus to the US Senate Agriculture Committee, which also needs to clear text for merging.

A Senate floor vote on the merged text would be the next step. If passed, the US House of Representatives would need to then pass the Bill to President Trump. The timing of the rollout of crypto-friendly legislation may ultimately hinge on whether the House makes changes to the merged text.

Crypto in America host Eleanor Terrett recently commented on the timings, stating:

“And March is the absolute earliest. Could even be the summer if the House decided to make changes to what the Senate sends them.”

Importantly, delays to the Market Structure Bill’s progress would challenge XRP’s bullish outlook, given previous price action.

For context, XRP surged 14.69% on July 17 after the House passed the Market Structure Bill to the Senate. However, the US government shutdown stalled the Bill’s progress in H2 2025. XRP fell from a July 18 all-time high of $3.66 to a December low of $1.7712 before the January recovery.

XRPUSD – Weekly Chart – 120126 XRP Bullish Price Outlook and Targets Strong demand for XRP-spot ETFs, increased XRP real-world utility, and the progress of the Market Structure Bill reaffirm a cautiously bullish short-term (1-4 weeks) outlook, with a $2.5 price target.

Meanwhile, increased optimism over the Senate passing the Market Structure Bill reinforces the positive longer-term price targets:

Medium-term (4-8 weeks): $3.0. Longer-term (8-12 weeks): $3.66. Key Risks to Bullish Scenario Several events could derail the positive outlook. These include:

The Bank of Japan announces a hawkish neutral interest rate (1.5%-2.5%), signaling multiple rate hikes. A higher neutral rate would likely trigger a yen carry trade unwind, which would challenge the short-term outlook. US economic data and the Fed are tempering expectations of an H1 2026 rate cut. Market Structure Bill faces partisan opposition. XRP-spot ETFs report outflows. These events would likely lead to a sharper decline, sending XRP below $2, which would indicate a bearish trend reversal.

Technical Analysis: Key Levels to Watch XRP fell 0.79% on Sunday, January 11, following the previous day’s 0.19% loss, closing at $2.0721. The token underperformed the broader crypto market cap, which gained 0.55%.

Six consecutive daily losses left XRP below the 50-day and 200-day EMAs, suggesting a bearish longer-term bias. Despite the technicals, the fundamentals remain bullish and dominate.

Key technical levels to watch include:

Support levels: $2.0, $1.75, and then $1.50. 50-day EMA resistance: $2.0717. 200-day EMA resistance: $2.3330. Resistance levels: $2.5, $3.0, and $3.66. Viewing the daily chart, a breakout above the 50-day EMA would open the door to testing $2.2. A move through $2.2 would bring the 200-day EMA into play. A sustained move through the EMAs would signal a bullish trend reversal, paving the way to the $2.5 resistance level.

Crucially, a breakout above the EMAs would reaffirm the bullish medium-term outlook and the longer-term (8-12 weeks) $3.66 price target.

Bitcoin price started a downside extension below $92,000. BTC is now recovering from $89,220 and might face barriers for a fresh increase near $92,000.

Bitcoin started a recovery wave above $90,000 and $90,500. The price is trading above $91,000 and the 100 hourly Simple moving average. There was a break above a bearish trend line with resistance at $90,750 on the hourly chart of the BTC/USD pair (data feed from Kraken). The pair might continue to move up if it stays above the $90,000 zone. Bitcoin Price Attempts Recovery Bitcoin price failed to stay above $91,500 and started a downside correction. BTC dipped below $92,000 and $91,200 to enter a short-term bearish zone.

The price even dipped below $90,500 and tested $90,000. A low was formed at $89,225 and the price is now attempting a fresh increase. There was a move above $90,500. The price climbed higher above the 23.6% Fib retracement level of the recent decline from the $93,770 swing high to the $89,225 low.

Besides, there was a break above a bearish trend line with resistance at $90,750 on the hourly chart of the BTC/USD pair. Bitcoin is now trading above $91,000 and the 100 hourly Simple moving average.

If the price remains stable above $90,500, it could attempt a fresh increase. Immediate resistance is near the $92,000 level and the 50% Fib retracement level of the recent decline from the $93,770 swing high to the $89,225 low. The first key resistance is near the $92,650 level.

Source: BTCUSD on TradingView.com The next resistance could be $93,500. A close above the $93,500 resistance might send the price further higher. In the stated case, the price could rise and test the $94,000 resistance. Any more gains might send the price toward the $94,500 level. The next barrier for the bulls could be $95,000 and $95,500.

Another Decline In BTC? If Bitcoin fails to rise above the $92,500 resistance zone, it could start another decline. Immediate support is near the $91,250 level. The first major support is near the $90,500 level.

The next support is now near the $90,000 zone. Any more losses might send the price toward the $89,250 support in the near term. The main support sits at $88,000, below which BTC might accelerate lower in the near term.

Technical indicators:

Hourly MACD – The MACD is now gaining pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for BTC/USD is now above the 50 level.

Major Support Levels – $91,250, followed by $90,500.

Major Resistance Levels – $92,500 and $93,500.

contributor

Posted: January 12, 2026

A massive shift is brewing as the BNB Foundation invests $200K in Chinese memecoins. This strategic move, paired with the Fermi Hard Fork, which is set to launch on the 14th of January, could fuel significant growth.

The upgrade promises faster transactions and better scalability, positioning BNB Chain as a leader in the memecoin narrative.

Charts show these memecoins gaining traction. How far will they rise before the 14th? Will they steadily climb or surge as the upgrade nears?

BNB Foundation’s $200K investment: What’s at stake? On the 11th of January, the BNB Foundation dropped $200K on Chinese memecoins, a signal to the sector’s potential.

$50K was invested in each of four memecoins: $币安人生, $哈基米, $我踏马来了, and $老子. Some of these coins have already experienced positive expansion, with $币安人生 rising by 26.56% in just 24 hours.

Source: CoinMarketCap

This strategic move adds credibility and shows a commitment to the growing memecoin trend.

With BNB’s positioning, these investments could play a central role in shaping the sector’s future. As the market grows, BNB’s early involvement could be crucial to the development of these projects.

Fermi: A game changer for memecoins? The Fermi Hard Fork will cut block times from 0.75 to 0.45 seconds, enabling faster transactions. This improvement will help memecoins thrive by supporting increased traffic and demand.

Source: X

With memecoins gaining popularity, the Fermi upgrade positions BNB Smart Chain as a strong competitor to platforms like Ethereum [ETH], Solana [SOL], Polygon [POL], and Avalanche [AVAX] in the memecoin space.

How far can memecoins run before the 14th? As the Fermi Hard Fork activation date approaches, memecoins are likely to experience heightened volatility.

The $200K investment has already sparked interest, and memecoin prices are expected to continue rising as traders speculate on the Fermi upgrade’s impact.

Whether this growth will continue until the 14th or face a correction remains to be seen.

With the upgrade just around the corner, memecoins could see significant gains as the market anticipates the improvements brought by the Fermi Hard Fork.

Final Thoughts BNB’s investment in memecoins and the Fermi upgrade position it for leadership in 2026. BNB’s early moves and technological advancements could shape the future of the evolving memecoin market.

Leading cryptocurrencies spiked on Sunday, but stock futures plunged after the Justice Department served subpoenas to the Federal Reserve.

CryptocurrencyGains +/-Price (Recorded at 9:15 p.m. ET)Bitcoin (CRYPTO: BTCEthereum(CRYPTO: ETH
               XRP(CRYPTO: XRP             Solana(CRYPTO: SOL             Dogecoin(CRYPTO: DOGE             )+0.97%$91,445.21)+1.21%$3,129.37)            -0.88%$2.07)            +3.88%$141.41)            +0.35%$0.1395Cryptos See Overnight SpikeBitcoin rallied in the evening, breaking past $91,500 as trading volume picked up dramatically. Volumes rose nearly 75% over the 24-hour period.

Similarly, Ethereum rose to nearly $3,150 in the evening hours, with trading volume surging 84% in the last 24 hours. 

The two assets are off to a good start in 2026, with Bitcoin up 4.42% and Ethereum up over 5.60%.

Over $140 million was liquidated from the cryptocurrency market in the last 24 hours, according to Coinglass, with nearly equal amounts of longs and shorts wiped out.

Bitcoin's open interest rose 0.69% in the last 24 hours, with nearly 70% of Binance traders with open BTC positions long on the apex cryptocurrency.

The “Fear sentiment continued to dominate the market, according to the Crypto Fear and Greed Index.

Top Gainers (24 Hours) 

Cryptocurrency (Market Cap>$100 M)Gains +/-Price (Recorded at 9:15 p.m. ET)StoryBUILDon                DeepBook Protocol      (IP )   +24%    $2.47(B )  +22.52%      $0.2758(DEEP )      +22.86%      $17.47The global cryptocurrency market capitalization stood at $3.1 trillion, following a modest increase of 0.45% in the last 24 hours.

Stocks Futures Plunge After Fed SubpoenaStock market futures fell overnight on Sunday. The Dow Jones Industrial Average Futures slipped 186 points, or 0.37%, as of 8:40 p.m. EDT.  Futures tied to the S&P 500 dipped 0.47%, while Nasdaq 100 Futures lost 0.72%.

The sell-offs come after Fed Chair Jerome Powell said that the central bank was hit with subpoenas threatening a criminal indictment over his testimony before the Senate Banking Committee last June.

Powell described the action as a result of not following the "preference of the President" on interest rates.

Where Is ETH Headed?Michaël van de Poppe, a widely followed cryptocurrency analyst and trader, noted that Ethereum is holding above a "crucial" resistance zone around $3,000- $3,100.

"That means that the likelihood towards new monthly highs has significantly increased. Great stuff," the analyst predicted.

EliZ, another popular cryptocurrency commentator, said Bitcoin remains "structurally weak" with no "credible" signs of a bottom.

"Any rebound at this stage is merely a technical reaction until the structure changes," EliZ added.

Photo Courtesy: KateStock on Shutterstock.com

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

BNB Chain is making a deliberate move to position itself at the center of the memecoin narrative. The BNB Foundation’s decision to invest $200,000 into Chinese language memecoins signals more than short-term speculation. It reflects a broader strategy to attract culture-driven liquidity ahead of a major network upgrade.

This move comes at a time when memecoins are regaining momentum across multiple chains. By acting early, BNB appears to be shaping demand rather than reacting to it.

Inside the $200K Investment Strategy On January 11, the BNB Foundation allocated $50,000 each to four Chinese-themed memecoins. The selection highlights a focus on community identity and regional narratives rather than purely technical innovation.

Some of these tokens have already responded strongly to the announcement. One of the projects posted a double-digit gain within a day, suggesting that traders view the Foundation’s backing as a credibility signal rather than a simple capital injection.

For emerging memecoins, visibility and perceived legitimacy often matter as much as liquidity. BNB’s involvement provides both.

Why This Matters Beyond Short-Term Price Action Memecoins thrive on attention, network activity, and low-friction transactions. By supporting these projects directly, BNB is encouraging developers and traders to build and trade within its ecosystem.

This strategy mirrors earlier cycles where chains that hosted popular memecoin runs saw sharp increases in usage, fees, and user onboarding. Early participation allows BNB to capture that activity rather than losing it to competing networks.

Fermi Hard Fork Adds Technical Firepower The upcoming Fermi Hard Fork strengthens the timing of this investment. By reducing block times significantly, BNB Smart Chain is preparing for higher transaction throughput and smoother user experiences.

Faster confirmation times are especially important for memecoin trading, where speed and cost can determine whether a network becomes the preferred venue during hype driven phases.

With this upgrade, BNB positions itself as a practical alternative to Ethereum, Solana, and other high-traffic chains competing for memecoin dominance.

What Happens as January 14 Approaches As the Fermi activation date nears, volatility across BNB-based memecoins is likely to increase. Traders tend to speculate on upgrades well before they go live, often pushing prices higher in anticipation.

Whether the current rally sustains or corrects will depend on broader market sentiment and how smoothly the upgrade unfolds. Still, the groundwork being laid suggests that BNB is aiming for lasting ecosystem growth rather than a short-lived pump.

If the upgrade delivers as expected, these early memecoin bets could mark the beginning of a larger expansion phase for BNB Chain.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Cryptocurrency investments are volatile and risky. Always conduct your research before making any investment decisions